Mindy Simpson to Coagulants
This is a "connection" page, showing publications Mindy Simpson has written about Coagulants.
Connection Strength
3.122
-
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.
Score: 0.728
-
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.
Score: 0.713
-
Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
Score: 0.700
-
Management of joint bleeding in hemophilia. Expert Rev Hematol. 2012 Aug; 5(4):459-68.
Score: 0.408
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
Score: 0.294
-
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017 09 25; 9:CD011441.
Score: 0.146
-
Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(?) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
Score: 0.134